Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT07491601
Recruiting Not applicable

PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery"

NCT07491601 · tracked via the Priya Life Science Germany tracker
Sponsor
Nicolas Schlegel
Phase
Not applicable
Started
2025-01-08
Last updated
2026-03-24

Condition(s) studied

Postoperative HypoparathyroidismPostsurgical HypoparathyroidismHypoparathyroidism Post-surgical

Investigational drug(s) / intervention(s)

Active vitamin DCalcium →

Active vitamin D: Application if parathyroid hormone level falls below normal

Calcium: Administered if parathyroid hormone level falls below normal

Study summary

This study aims to investigate whether an earlier measurement of parathyroid hormone can reduce the number of patients who develop symptomatic hypoparathyroidism. This will provide evidence for a clear algorithm to address this issue after thyroid surgery. It will lead to an improvement in quality of life and a reduction in the distress experienced by affected patients. In addition, it is conceivable that patients' hospital stay could be shortened.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * Thyroidectomy or bilateral thyroid resection of any indication * Written informed consent obtained after detailed patient information and provision of an information sheet Exclusion Criteria: * Age ≤ 18 years * Concomitant parathyroid disease (primary or secondary hyperparathyroidism, pre-existing hypoparathyroidism of any cause) * Previous surgery in the neck region * Pregnancy or breastfeeding * Inability to attend study visits * Participation in another study that interferes with the endpoints * Missing or inadequate patient information

Primary outcome measure(s)

  • Symptomatic hypoparathyroidism (symptom score) with hypocalcemia — within hospital stay (0-48hours after bilateral thyroid surgery)
    Symptomatic hypoparathyroidism is defined as the presence of one or more symptoms reported in the questionnaire.

Trial sites (1)

FacilityCityRegionStatus
Dept. Surgery I; University Hospital Wuerzburg Würzburg Bavaria Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07491601 on ClinicalTrials.gov ↗ ← All trials in Germany